Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial

SpringerPlus

Table 5 Possibly or probably drug-related adverse events

Adverse event	Placebo	NEPA_200/0.5	NEPA_600/1.5	Moxifloxacin
Number of subjects (%)	(N = 50)	(N = 49)	(N = 49)	(N = 49)
Cardiac disorders
Palpitations	0	0	1 (2.0)	0
Gastrointestinal disorders
Abdominal pain upper	0	2 (4.1)	0	0
Constipation	0	3 (6.1)	2 (4.1)	0
Dry mouth	1 (2.0)	0	0	0
Dyspepsia	1 (2.0)	0	0	0
Flatulence	1 (2.0)	0	0	0
Nausea	0	0	0	1 (2.0)
General disorders and administration-site conditions
Fatigue	0	1 (2.0)	0	1 (2.0)
Thirst	0	0	0	1 (2.0)
Musculoskeletal and connective tissue disorders
Muscle twitching	1 (2.0)	0	0	0
Pain in extremity	0	0	1 (2.0)	0
Sensation of heaviness	1 (2.0)	0	0	0
Nervous system disorders
Dizziness	1 (2.0)	0	1 (2.0)	3 (6.1)
Headache	5 (10.0)	2 (4.1)	5 (10.2)	2 (4.1)
Somnolence	0	0	1 (2.0)	0
Psychiatric disorders
Anxiety	0	0	1 (2.0)	0
Euphoric mood	0	0	1 (2.0)	0
Total	9 (18.0)	8 (16.3)	10 (20.4)	8 (16.3)

NEPA_200/0.5: 200 mg netupitant (50 mg + 150 mg) + 0.50 mg palonosetron (1 × 0.50 mg).
NEPA_600/1.5: 600 mg netupitant (4 × 150 mg) + 1.50 mg palonosetron (3 × 0.50 mg).
Percentages are based on N.